Patents by Inventor Takanori Yokota

Takanori Yokota has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240158790
    Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5? terminal side of the region, (c) one or more nucleotide analogs located on 3? terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.
    Type: Application
    Filed: December 21, 2023
    Publication date: May 16, 2024
    Applicants: National University Corporation Tokyo Medical and Dental University, Osaka University
    Inventors: Takanori Yokota, Kazutaka Nishina, Satoshi Obika, Hidehiro Mizusawa
  • Publication number: 20240117346
    Abstract: In an embodiment, an object of the present invention is to provide a double-stranded nucleic acid complex having a novel structure. In an embodiment, the present invention relates to a nucleic acid complex comprising a first nucleic acid strand and a second nucleic acid strand, wherein said first nucleic acid strand: (1) is capable of hybridizing to at least a part of a target transcriptional product; (2) has an antisense effect on the target transcriptional product; and (3) is a gapmer comprising a central region, and a 5? wing region and a 3? wing region, said second nucleic acid strand comprises at least one sugar-unmodified central region (first exposed region) consisting of one sugar-unmodified ribonucleoside or two or three contiguous sugar-unmodified ribonucleosides linked by an internucleoside bond, which is or are complementary to a part of said first nucleic acid strand, and said first nucleic acid strand is annealed to said second nucleic acid strand.
    Type: Application
    Filed: October 9, 2020
    Publication date: April 11, 2024
    Applicants: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori Yokota, Tetsuya Nagata, Hiroki Yamada, Hideki Furukawa, Takatoshi Yogo, Kenichi Miyata, Akio Uchida, Naoki Tomita
  • Publication number: 20230414765
    Abstract: A polymer represented by the following formula (I): wherein each symbol is as described in the specification, is useful as a drug carrier in effectively delivering a drug to a target site.
    Type: Application
    Filed: September 8, 2023
    Publication date: December 28, 2023
    Applicants: AGC INC., THE UNIVERSITY OF TOKYO, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Mihoko HARA, Rintaro HARA, Kanjiro MIYATA, Mitsuru NAITO, Takanori YOKOTA
  • Patent number: 11851654
    Abstract: An object of the invention is to provide a low toxicity antisense nucleic acid medicine that can modulate expression of a target transcriptional product in the central nervous system and other sites of a subject. Provided is a low toxicity composition for modulating expression of a target transcriptional product in a site such as the central nervous system of a subject, having a nucleic acid complex formed by annealing together a first nucleic acid strand having an antisense oligonucleotide region with respect to the target transcriptional product, and a second nucleic acid strand having a complementary region that is complementary to at least part of the first nucleic acid strand.
    Type: Grant
    Filed: March 19, 2019
    Date of Patent: December 26, 2023
    Assignee: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori Yokota, Tetsuya Nagata, Kotaro Yoshioka
  • Publication number: 20230295628
    Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.
    Type: Application
    Filed: February 2, 2023
    Publication date: September 21, 2023
    Applicants: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori Yokota, Tetsuya Nagata, Hideki Furukawa, Yasuo Nakagawa, Takatoshi Yogo, Ryosuke Tokunoh, Shigekazu Sasaki, Kosuke Hidaka, Tomohiro Seki, Kenichi Miyata, Akio Uchida
  • Patent number: 11674141
    Abstract: The present invention provides an antisense nucleic acid medicine that can modulate expression of a target transcriptional product in an ischemic site of a subject. The present invention also provides a composition for modulating expression of a target transcriptional product in an ischemic site of a subject, having a nucleic acid complex formed by annealing together a first nucleic acid strand having an antisense oligonucleotide region with respect to the target transcriptional product, and a lipid-conjugated second nucleic acid strand having a complementary region that is complementary to at least part of the first nucleic acid strand.
    Type: Grant
    Filed: February 27, 2019
    Date of Patent: June 13, 2023
    Assignee: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori Yokota, Satoru Ishibashi
  • Publication number: 20230174981
    Abstract: A double-stranded nucleic acid complex that can have an excellent activity is provided. In one embodiment, the present invention relates to a double-stranded nucleic acid complex having a first nucleic acid strand and a second nucleic acid strand. The first nucleic acid strand is capable of hybridizing to at least part of a target gene or a transcription thereof, has an antisense effect on the target gene or transcription product thereof, and has at least two morpholino nucleic acids The second nucleic acid strand has a base sequence complementary to the first nucleic acid strand. The first nucleic acid strand is annealed to the second nucleic acid strand.
    Type: Application
    Filed: March 12, 2021
    Publication date: June 8, 2023
    Applicant: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori YOKOTA, Tetsuya NAGATA
  • Patent number: 11597928
    Abstract: Developed and provided is: a nucleic acid agent that is efficiently delivered to the central nervous system, to which drug delivery is inhibited by the blood brain barrier mechanism, and that provides an antisense effect to a target transcription product at the delivery site; and a composition containing such a nucleic acid agent. Provided is a double-stranded nucleic acid complex consisting of a first nucleic acid strand and a second nucleic acid strand that are annealed to each other; wherein the first nucleic acid strand hybridizes with part of a target transcription product and has an antisense effect on the target transcription product; and wherein the second nucleic acid strand includes a base sequence complementary to the first nucleic acid strand and is conjugated to a phosphatidylethanolamine or an analog thereof.
    Type: Grant
    Filed: March 13, 2019
    Date of Patent: March 7, 2023
    Assignees: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori Yokota, Tetsuya Nagata, Hideki Furukawa, Yasuo Nakagawa, Takatoshi Yogo, Ryosuke Tokunoh, Shigekazu Sasaki, Kosuke Hidaka, Tomohiro Seki, Kenichi Miyata, Akio Uchida
  • Publication number: 20230024153
    Abstract: The present invention provides a composition and a method for efficiently delivering a nucleic acid agent to the central nervous system and/or the retina and bringing about antisense effects. Provided is a composition for reducing the expression level of a target transcription product in the central nervous system and/or retina of a subject, the composition including a nucleic acid complex that includes a first nucleic acid strand and a second nucleic acid strand, wherein: the first nucleic acid strand comprises a base sequence capable of hybridizing with at least part of the target transcription product and has an antisense effect on the target transcription product; the second nucleic acid strand comprises a base sequence complementary to the first nucleic acid strand and is conjugated to tocopherol, cholesterol, or an analog thereof; and the first nucleic acid strand is annealed to the second nucleic acid strand.
    Type: Application
    Filed: July 27, 2022
    Publication date: January 26, 2023
    Applicant: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori Yokota, Tetsuya Nagata
  • Publication number: 20220370491
    Abstract: The object of the present invention is to provide a nucleic acid agent that is efficiently delivered to the nervous system, for example, the central nervous system to which drug delivery can be prevented by BBB, and produces an antisense effect on the target transcriptional product at the delivery site, and a composition comprising the same. In an embodiment, the present invention provides a double-stranded nucleic acid complex formed by annealing a first nucleic acid strand that hybridizes to a part of a target transcriptional product and has an antisense effect on the target transcriptional product, and a second nucleic acid strand that comprises a base sequence complementary to the first nucleic acid strand and is bound to a C22-35 alkyl group optionally substituted with a hydroxy group or an analog thereof.
    Type: Application
    Filed: September 16, 2020
    Publication date: November 24, 2022
    Applicants: National University Corporation Tokyo Medical and Dental University, Takeda Pharmaceutical Company Limited
    Inventors: Takanori Yokota, Testuya Nagata, Hideki Furukawa, Takatoshi Yogo, Yasuo Nakagawa, Shigekazu Sasaki, Ryosuke Tokunoh, Tomohiro Seki, Kosuke Hidaka, Fumiaki Kikuchi, Osamu Kubo, Takahito Kasahara, Takuto Kojima, Junsi Wang, Norihito Tokunaga
  • Publication number: 20220307019
    Abstract: A double-stranded nucleic acid complex is a double-stranded nucleic acid complex including a first nucleic acid strand and a second nucleic acid strand bonded to each other, the second nucleic acid strand including a complementary region having a base sequence complementary to the first nucleic acid strand; the first nucleic acid strand including natural nucleosides and non-natural nucleosides; some of the nucleosides in at least one nucleic acid strand selected from the group consisting of the first nucleic acid strand and the second nucleic acid strand being bonded together by bonds including asymmetric phosphorus atoms; and absolute configurations of the asymmetric phosphorus atoms being regulated.
    Type: Application
    Filed: March 25, 2020
    Publication date: September 29, 2022
    Applicants: National University Corporation Tokyo Medical and Dental University, Wave Life Sciences Ltd
    Inventors: Takanori YOKOTA, Takeshi WADA, Mamoru SHIMIZU
  • Patent number: 11433089
    Abstract: The present invention provides a composition and a method for efficiently delivering a nucleic acid agent to the central nervous system and/or the retina and bringing about antisense effects. Provided is a composition for reducing the expression level of a target transcription product in the central nervous system and/or retina of a subject, the composition including a nucleic acid complex that includes a first nucleic acid strand and a second nucleic acid strand, wherein: the first nucleic acid strand comprises a base sequence capable of hybridizing with at least part of the target transcription product and has an antisense effect on the target transcription product; the second nucleic acid strand comprises a base sequence complementary to the first nucleic acid strand and is conjugated to tocopherol, cholesterol, or an analog thereof; and the first nucleic acid strand is annealed to the second nucleic acid strand.
    Type: Grant
    Filed: September 25, 2017
    Date of Patent: September 6, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori Yokota, Tetsuya Nagata
  • Publication number: 20220175817
    Abstract: A nucleic acid complex that exhibits an excellent antisense effect in the skeletal muscle and/or heart muscle, and a composition for treating or preventing a muscle disease that develops in the skeletal muscle, heart muscle, and the like having the nucleic acid complex as an active ingredient is disclosed. Also provided is a double-stranded nucleic acid complex in which a first nucleic acid strand that hybridizes to the transcription product of a target gene and has an antisense effect on the transcription product is annealed with a second nucleic acid strand that has a base sequence complementary to the first nucleic acid strand and is bound to cholesterol or analog thereof.
    Type: Application
    Filed: April 8, 2020
    Publication date: June 9, 2022
    Applicant: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori YOKOTA, Tetsuya NAGATA
  • Publication number: 20220154185
    Abstract: Provided is a nucleic acid inhibiting a function of a target miRNA. Provided is a double-stranded nucleic acid complex comprising a first nucleic acid strand of 6 to 30 nucleotide length that hybridizes to a target miRNA to inhibit a function of the target miRNA, and a second nucleic acid strand complementary to the first nucleic acid strand, wherein the first nucleic acid strand is a mixmer comprising a natural nucleoside and a non-natural nucleoside, and the second nucleic acid strand comprises at least one of one or more modified internucleoside linkages and one or more sugar modified nucleosides.
    Type: Application
    Filed: February 2, 2022
    Publication date: May 19, 2022
    Applicant: National University Corporation Tokyo Medical and Dental University
    Inventors: Takanori Yokota, Kotaro Yoshioka
  • Publication number: 20220135972
    Abstract: An object of the present invention is to provide a double-stranded nucleic acid complex having a reduced number of PS modifications in an antisense strand and maintaining an antisense effect. An optimal PS modification pattern for double-stranded nucleic acid complexes is disclosed. Such a nucleic acid complex comprising an antisense strand having an optimal PS modification pattern has a characteristic of having low toxicity and high bioavailability. The double-stranded nucleic acid complex comprising an antisense strand having an optimal PS modification pattern according to the present invention is useful when used as a nucleic acid drug that utilizes inhibition of expression of a specific gene (knockdown), activity that changes the function of coating or non-coding RNA for a specific gene, or activity that changes the function of RNA by inducing exon skipping during processing of pre-mRNA for a specific gene.
    Type: Application
    Filed: February 20, 2020
    Publication date: May 5, 2022
    Applicant: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori YOKOTA, Rintaro HARA, Tetsuya NAGATA, Hideki KIZAWA, Koh TAKAGI
  • Patent number: 11260134
    Abstract: Provided is a nucleic acid strand that can efficiently deliver an antisense oligonucleotide into the body, particularly a nucleic acid complex comprising a first nucleic acid strand and a second nucleic acid strand, wherein the first nucleic acid strand includes a base sequence that is capable of hybridizing with at least a portion of a target transcription product, and exerts an antisense effect on the target transcription product; the second nucleic acid strand includes a complementary region having a base sequence complementary to the first nucleic acid strand and at least one overhang region located on the 5? and/or 3? side of the complementary region; and the first nucleic acid strand is annealed to the complementary region in the second nucleic acid strand.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: March 1, 2022
    Assignee: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori Yokota, Kotaro Yoshioka
  • Patent number: 11234995
    Abstract: The present invention can provide a nucleic acid medicine which has a higher effect and a more prolonged effect of inhibiting the expression of ?-synudein can be provided. Disclosed is the oligonucleotide or a pharmacologically acceptable salt thereof, the oligonucleotide containing at least one nucleoside structure represented by Formula (I): (where each of Base and A are defined substituent or structure), can bind to an ?-synudein gene, has activity for inhibiting expression of the ?-synudein gene, and is complementary to the ?-synudein gene, and the oligonucleotide has a length of twelve to twenty bases.
    Type: Grant
    Filed: January 5, 2017
    Date of Patent: February 1, 2022
    Assignees: OSAKA UNIVERSITY, NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY, NATIONAL INSTITUTES OF BIOMEDICAL INNOVATION, HEALTH AND NUTRITION
    Inventors: Masayuki Nakamori, Hideki Mochizuki, Satoshi Obika, Takanori Yokota, Tetuya Nagata, Yuya Kasahara
  • Publication number: 20210340540
    Abstract: A method of reducing the level of a transcription product in a cell comprising contacting with the cell a composition comprising a double-stranded nucleic acid complex comprising a first nucleic acid strand annealed to a second nucleic acid strand, wherein: (i) the first nucleic acid strand hybridizes to the transcription product and comprises (a) a region consisting of at least 4 consecutive nucleotides that are recognized by RNase H when the strand is hybridized to the transcription product, (b) one or more nucleotide analogs located on 5? terminal side of the region, (c) one or more nucleotide analogs located on 3? terminal side of the region and (d) a total number of nucleotides and nucleotide analogs ranging from 8 to 35 nucleotides and (ii) the second nucleic acid strand comprises (a) nucleotides and optionally nucleotide analogs and (b) at least 4 consecutive RNA nucleotides.
    Type: Application
    Filed: May 27, 2021
    Publication date: November 4, 2021
    Applicants: National University Corporation Tokyo Medical and Dental University, Osaka University
    Inventors: Takanori Yokota, Kazutaka Nishina, Satoshi Obika, Hidehiro Mizusawa
  • Publication number: 20210317455
    Abstract: This invention provides a nucleic acid that can attenuate toxicity caused by abnormal accumulation of RNA-binding proteins in cells and can be used for prevention or treatment of neurodegenerative diseases and an agent for prevention or treatment of neurodegenerative diseases containing such nucleic acid. Such nucleic acid comprises a repeat RNA consisting of nucleotides represented by the formula: (U(Me)GX1X2X3 . . . Xm)n, wherein U(Me) is 2?-O-Me-modified; X1, X2, X3, . . . Xm may or may not be present, each independently represent A, C, G, or U in the presence thereof, and may be the same or different; m is 1 to 10; G, X1, X2, X3, . . . Xm may or may not be each independently 2?-O-Me-modified; and n is 4 to 15. The agent for prevention or treatment of neurodegenerative diseases induced by abnormal accumulation of TDP-43 in cells comprises such nucleic acid as an active ingredient.
    Type: Application
    Filed: August 2, 2019
    Publication date: October 14, 2021
    Applicant: NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY
    Inventors: Takanori YOKOTA, Fumika SAKAUE
  • Publication number: 20210290143
    Abstract: A bioelectric current estimation method includes acquiring position information of a nerve in a measurement target region of a subject for which magnetic data is measured with a magnetic sensor, the position information of the nerve being acquired based on a nerve image included in a morphological image of the measurement target region; acquiring a positional relationship between a position of the nerve and a position of the magnetic sensor, based on the acquired position information of the nerve and position information of the magnetic sensor when the magnetic sensor is positioned to face the measurement target region; and estimating a neural activity current, which is generated in association with neural activity of the subject, based on the acquired positional relationship and the magnetic data of the measurement target region measured by the magnetic sensor.
    Type: Application
    Filed: March 18, 2021
    Publication date: September 23, 2021
    Applicants: Ricoh Company, Ltd., National University Corporation Tokyo Medical and Dental University
    Inventors: Taishi WATANABE, Shigenori KAWABATA, Takanori YOKOTA, Miho AKAZA, Hiroshi DEGUCHI, Sukchan KIM, Yuki MIYANO